151 related articles for article (PubMed ID: 30770558)
1. Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia.
Haybar H; Shahrabi S; Rezaeeyan H; Jodat H; Saki N
J Cell Physiol; 2019 Sep; 234(9):14500-14506. PubMed ID: 30770558
[TBL] [Abstract][Full Text] [Related]
2. The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
Wang R; Zhang J; Wang S; Wang M; Ye T; Du Y; Xie X; Ye J; Sun G; Sun X
Molecules; 2019 Feb; 24(3):. PubMed ID: 30717322
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide-induced cardiotoxicity triggers ferroptosis in cardiomyoblast cells.
Wang L; Liu S; Gao C; Chen H; Li J; Lu J; Yuan Y; Zheng X; He H; Zhang X; Zhang R; Zhang Y; Wu Y; Lin W; Zheng H
Hum Exp Toxicol; 2022; 41():9603271211064537. PubMed ID: 35195477
[TBL] [Abstract][Full Text] [Related]
4. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
5. An Overview on Arsenic Trioxide-Induced Cardiotoxicity.
Vineetha VP; Raghu KG
Cardiovasc Toxicol; 2019 Apr; 19(2):105-119. PubMed ID: 30617460
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic Acid A Ameliorates Arsenic Trioxide-Induced Cardiotoxicity Through Decreasing Cardiac Mitochondrial Injury and Promotes Its Anticancer Activity.
Zhang JY; Wang M; Wang RY; Sun X; Du YY; Ye JX; Sun GB; Sun XB
Front Pharmacol; 2018; 9():487. PubMed ID: 29867492
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan protects against arsenic trioxide induced cardiotoxicity in vivo and in vitro.
Wu Z; Chen H; Lin L; Lu J; Zhao Q; Dong Z; Hai X
Toxicol Res (Camb); 2022 Jun; 11(3):451-459. PubMed ID: 35782642
[TBL] [Abstract][Full Text] [Related]
9.
Li Y; Wan R; Liu J; Liu W; Ma L; Zhang H
Front Physiol; 2022; 13():1004605. PubMed ID: 36589437
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
11. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Leukemia; 2013 Feb; 27(2):315-24. PubMed ID: 22751450
[TBL] [Abstract][Full Text] [Related]
13. Crocin ameliorates arsenic trioxide‑induced cardiotoxicity via Keap1-Nrf2/HO-1 pathway: Reducing oxidative stress, inflammation, and apoptosis.
Liang Y; Zheng B; Li J; Shi J; Chu L; Han X; Chu X; Zhang X; Zhang J
Biomed Pharmacother; 2020 Nov; 131():110713. PubMed ID: 32920515
[TBL] [Abstract][Full Text] [Related]
14. Calcium homeostasis and endoplasmic reticulum stress are involved in Salvianolic acid B-offered protection against cardiac toxicity of arsenic trioxide.
Zhang JY; Zhang B; Wang M; Wang W; Liao P; Sun GB; Sun XB
Oncotarget; 2017 Nov; 8(57):97384-97393. PubMed ID: 29228618
[TBL] [Abstract][Full Text] [Related]
15. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
17. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.
Zheng Y; Mao YF; Zhao HJ; Chen L; Wang LN; Zhang YX; Hu J; Li JM; Li XY; Zhu HM
Exp Hematol Oncol; 2021 Feb; 10(1):10. PubMed ID: 33549147
[TBL] [Abstract][Full Text] [Related]
18. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia S
Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587
[TBL] [Abstract][Full Text] [Related]
20. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
